VistaGen Therapeutics, Inc. Common Stock
|Range Today||$1.20 - $1.26|
|52 Week Range||$0.69 - $3.71|
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Its product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to standard antidepressants. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.